Genmab secures rights to Revitope’s proprietary, conditional T Cell Engagement (TCE) TwoGATE™ technology for conducting research against multiple drug target pairs with options for exclusive worldwide development and commercialization for up to three resulting products Revitope to receive…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.